Investigating a genetic polymorphism in Egyptian patients with psoriatic arthritis
Official title: Card14gene (rs34367357 ) Polymorphism in Egyptian Psoriatic and Psoriatic Arthritis Patient and Its Relation With Response to Methotrexate
Run by South Valley University · NCT06870500 · Data updated 2026-11-12
This study is testing if a specific gene variation affects how Egyptian patients with psoriatic arthritis respond to treatment with methotrexate compared to a placebo.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 50 Years |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | South Valley University Academic / other |
| Drugs / interventions | methotrexate |
| Locations | 1 site (Qina) |
| Status | Recruiting |
| Started | March 5, 2025 |
| Main results expected | March 1, 2026 |
| Study ends | March 10, 2026 |
| Registry record updated | March 11, 2025 |
| Trial ID | NCT06870500 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are Egyptian adults aged 18 and older with moderate to severe psoriasis and possible psoriatic arthritis.
✕Probably not a fit
Patients with other autoimmune conditions, pregnancy, or those currently on immunosuppressive therapies may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study examines the Card14 gene polymorphism (rs34367357) in Egyptian patients suffering from psoriatic arthritis, a chronic inflammatory condition associated with psoriasis. It aims to understand the genetic factors contributing to the disease's severity and response to treatment. Participants will receive either methotrexate or a placebo, with their responses monitored to assess the effectiveness of the treatment. The study seeks to clarify the role of genetic predisposition in the management of psoriatic arthritis.
Why it matters
Potential benefit: If successful, this study could lead to more personalized treatment strategies for patients with psoriatic arthritis based on their genetic profiles.
How similar studies have gone: While the specific genetic focus may be novel, studies on genetic polymorphisms in autoimmune diseases have shown varying degrees of success in understanding disease mechanisms and treatment responses.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients aged 18 years and above. * Patients having psoriasis diagnosed clinically and who have a severity grade of moderate to severe, defined as a Psoriasis Area and Severity Index (PASI) score from 5- 10 % of body surface area, and involvement of greater than 10% of the body surface area (BSA) with or without psoriatic arthritis Exclusion Criteria: * Patients with other autoimmune conditions (e.g., rheumatoid arthritis, systemic lupus erythematosus). * Pregnancy and lactation. * Patients currently undergoing immunosuppressive or systemic therapies. * Patients with known genetic disorders affect immune system function. * Patients with liver or kidney impairment. * Patients with allergy or contraindication to methotrexate. * Patients with active or uncontrolled infections, including chronic infections like tuberculosis.
Where it's running
-
Qina University hospital, South Valley University Hospital
Qina, Egypt Recruiting
Study contacts
- Study coordinator: Marwa Naguib Ahmed, MSc
- Email: omarahmed331166@yahoo.com
- Phone: +201099283315
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
TRAF3IP2 gene variation (rs13190932) in people with psoriasis and psoriatic arthritis
This trial will test whether the TRAF3IP2 (rs13190932) gene variant changes how adults with psoriasis or psoriatic arthritis respond to methotrexate treatment.
-
Can older adults with breast cancer tolerate a dense CMF chemo schedule
This study tests whether giving a condensed CMF chemotherapy regimen is feasible for people 70 and older with breast cancer.
-
HLA B Leader in Psoriatic Arthritis
This study tests whether the HLA B leader gene is more common in people with psoriatic arthritis than in healthy individuals.
-
Anti-CD25 antibody to prevent acute GVHD after haploidentical stem cell transplant
This study tests whether an anti-CD25 antibody can better prevent acute graft-versus-host disease after haploidentical hematopoietic stem cell transplantation compared with the usual methotrexate-based approach.
-
TaVNS for Psoriatic Arthritis in Adults
This study tests whether non-invasive taVNS can help reduce disease activity and improve pain and quality of life in adults with psoriatic arthritis.
-
R-PMDT Regimen for Newly Diagnosed PCNSL
This study tests the R-PMDT treatment approach in people newly diagnosed with primary CNS lymphoma to see how many respond.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.